|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Matrix metalloproteinase-11 (MMP-11) has been observed in most invasive human carcinomas.
|
28427180 |
2017 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Stromelysin-3 (ST3, MMP-11) has been shown to be strongly overexpressed in stromal fibroblasts of most invasive human carcinomas.
|
15509588 |
2005 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Stromelysin-3 (ST3), a matrix metalloproteinase (MMP) expressed in aggressive carcinomas, has been shown to promote tumor development in different in vivo experimental models.
|
10734321 |
2000 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Statistically significant associations were found in the invasive carcinomas between ST-3 expression and lymphatic vessel invasion, an infiltrative invasive pattern, and invasion into at least the muscle layer (pT2,3,4 v pT1).
|
10923925 |
2000 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Epithelial expression of stromelysin 3 predominated in squamous and basaloid carcinomas (P = 0.0005) and was inversely correlated to squamous differentiation (P = 0.018).
|
9137088 |
1997 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Human stromelysin-3 and interstitial collagenase are matrix metalloproteinases whose expression by stromal cells in several types of carcinomas has been associated with cancer progression.
|
9111003 |
1997 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Most of the colon carcinomas (26 of 28) induced an expression of ST-3 in the directly adjacent stroma.
|
8955621 |
1996 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Stromelysin-3 (ST3) is a matrix metalloproteinase expressed in human carcinomas in ways suggesting that it may play a role in tumor progression.
|
8621777 |
1996 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Stromelysin-3 (ST3) is a matrix metalloproteinase which is expressed in fibroblastic cells of most human invasive carcinomas and represents a potential new prognostic indicator.
|
7591307 |
1995 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of ST3 was mainly confined to invasive carcinomas and was observed less frequently in pure ductal carcinoma in situ (DCIS) lesions.
|
8026874 |
1994 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The ST3 gene is overexpressed in most types of human carcinomas, including breast carcinoma where ST3 RNA was detected in 95% (99 of 104) of invasive primary tumors.
|
7518738 |
1994 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Localization by in situ hybridization of mRNAs encoding stromelysin 3 and tissue inhibitors of metallo-proteinases TIMP-1 and TIMP-2 in human head and neck carcinomas.
|
8302724 |
1993 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, there was a highly significant positive correlation (P < 0.0001) between ST3 RNA levels and local invasiveness by the cancer cells, suggesting that enhanced expression of the ST3 gene may contribute to the neoplastic phenotype in head and neck carcinomas.
|
7677979 |
1993 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Stromelysin-3 (ST3) is a putative new matrix metalloproteinase (MMP) which may play a role in the progression of human carcinomas, and exhibits unique structural and functional characteristics among the MMP family.
|
8435474 |
1993 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Stromelysin-3 mRNA was found more often in estrogen-receptor-positive carcinomas and in histological grade-1 carcinomas.
|
8244574 |
1993 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The ST3 gene is expressed in all invasive breast carcinomas, in a number of their metastases, and in some in situ carcinomas where the probability of detecting ST3 transcripts correlates with the known risk of these carcinomas to become invasive.
|
8446598 |
1993 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We suggest that ST3 gene expression, which was also observed in fibroblasts during cutaneous scar formation, corresponds to a normal wound-healing response that has been subverted in carcinomas.
|
1469302 |
1992 |